Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome.
<h4>Objectives</h4>The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0227142&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043340243861504 |
|---|---|
| author | Julian Jehle Hanna Goerich Laura Bindila Beat Lutz Georg Nickenig Vedat Tiyerili |
| author_facet | Julian Jehle Hanna Goerich Laura Bindila Beat Lutz Georg Nickenig Vedat Tiyerili |
| author_sort | Julian Jehle |
| collection | DOAJ |
| description | <h4>Objectives</h4>The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given their short half-life and their autocrine/paracrine mechanism of action, eCB levels in venous blood samples might not reflect arterial or coronary eCB concentrations. The aim of this cross-sectional study was to identify the local concentration profile of eCB and to detect whether and how this concentration profile changes in CAD and NSTEMI versus patients without CAD.<h4>Methods and results</h4>83 patients undergoing coronary angiography were included in this study. Patients were divided into three groups based on their definite diagnosis of a) no CAD, b) stable CAD, or c) non-ST-segment elevation myocardial infarction (NSTEMI). Blood was drawn from the arterial sheath and the aorta in all patients and additionally distal to the culprit coronary lesion in CAD- and NSTEMI patients. 2-AG levels varied significantly between patient groups and between the sites of blood extraction. The lowest levels were detected in patients without CAD; the highest 2-AG concentrations were detected in NSTEMI patients and in the coronary arteries. Peripheral 2-AG levels were significantly higher in NSTEMI patients (107.4 ± 28.4 pmol/ml) than in CAD- (17.4 ± 5.4 pmol/ml; p < 0.001), or no-CAD patients (23.9 ± 7.1 pmol/ml; p < 0.001). Moreover, coronary 2-AG levels were significantly higher in NSTEMI patients than in CAD patients (369.3 ± 57.2 pmol/ml vs. 240.1 ± 25.3 pmol/ml; p = 0.024).<h4>Conclusions</h4>2-AG showed significant variability in arterial blood samples drawn from distinct locations. Possibly, lesional macrophages synthesise 2-AG locally, which thereby contributes to endothelial dysfunction and local inflammation. |
| format | Article |
| id | doaj-art-ece2ae8fe3374ddd9e21dd3b8134403a |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-ece2ae8fe3374ddd9e21dd3b8134403a2025-08-20T02:55:16ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011412e022714210.1371/journal.pone.0227142Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome.Julian JehleHanna GoerichLaura BindilaBeat LutzGeorg NickenigVedat Tiyerili<h4>Objectives</h4>The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given their short half-life and their autocrine/paracrine mechanism of action, eCB levels in venous blood samples might not reflect arterial or coronary eCB concentrations. The aim of this cross-sectional study was to identify the local concentration profile of eCB and to detect whether and how this concentration profile changes in CAD and NSTEMI versus patients without CAD.<h4>Methods and results</h4>83 patients undergoing coronary angiography were included in this study. Patients were divided into three groups based on their definite diagnosis of a) no CAD, b) stable CAD, or c) non-ST-segment elevation myocardial infarction (NSTEMI). Blood was drawn from the arterial sheath and the aorta in all patients and additionally distal to the culprit coronary lesion in CAD- and NSTEMI patients. 2-AG levels varied significantly between patient groups and between the sites of blood extraction. The lowest levels were detected in patients without CAD; the highest 2-AG concentrations were detected in NSTEMI patients and in the coronary arteries. Peripheral 2-AG levels were significantly higher in NSTEMI patients (107.4 ± 28.4 pmol/ml) than in CAD- (17.4 ± 5.4 pmol/ml; p < 0.001), or no-CAD patients (23.9 ± 7.1 pmol/ml; p < 0.001). Moreover, coronary 2-AG levels were significantly higher in NSTEMI patients than in CAD patients (369.3 ± 57.2 pmol/ml vs. 240.1 ± 25.3 pmol/ml; p = 0.024).<h4>Conclusions</h4>2-AG showed significant variability in arterial blood samples drawn from distinct locations. Possibly, lesional macrophages synthesise 2-AG locally, which thereby contributes to endothelial dysfunction and local inflammation.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0227142&type=printable |
| spellingShingle | Julian Jehle Hanna Goerich Laura Bindila Beat Lutz Georg Nickenig Vedat Tiyerili Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. PLoS ONE |
| title | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. |
| title_full | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. |
| title_fullStr | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. |
| title_full_unstemmed | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. |
| title_short | Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. |
| title_sort | endocannabinoid 2 arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0227142&type=printable |
| work_keys_str_mv | AT julianjehle endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT hannagoerich endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT laurabindila endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT beatlutz endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT georgnickenig endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome AT vedattiyerili endocannabinoid2arachidonoylglyceroliselevatedinthecoronarycirculationduringacutecoronarysyndrome |